Skip to main content
Signal8
Launch Terminal

Bausch Health Companies Inc. (BHC)

Bausch Health Companies Inc., together with its associated entities, is engaged in the development, manufacturing, and commercialization of a diverse portfolio of pharmaceutical products, medical devices, and over-the-counter remedies. Its primary therapeutic focus areas include ophthalmology, digestive health, and dermatology. The enterprise conducts its operations through five principal divisions: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment is dedicated to vision care, encompassing surgical instruments, consumer eye health products, and ophthalmic pharmaceuticals. Salix specializes in delivering gastroenterology-specific products exclusively within the United States. The International Rx division markets Solta products, a range of branded and generic pharmaceuticals, OTC items, medical devices, and Bausch + Lomb offerings across diverse geographies including Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. Ortho Dermatologics focuses on dermatological products in the U.S., in addition to distributing Solta's medical aesthetic devices globally. Finally, the Diversified Products segment supplies pharmaceutical solutions for neurology and other therapeutic categories, as well as generic medications and dental products, all within the U.S. The company was formerly known as Valeant Pharmaceuticals International, Inc., officially changing its name to Bausch Health Companies Inc. in July 2018. Its corporate headquarters are located in Laval, Canada.

Sector: Pharmaceutical Preparations

Industry: Drug Manufacturers - Specialty & Generic

Bausch Health Companies Inc. logo

Bausch Health Companies Inc.

NYSE:BHCHealthcare
-7.97%$8.20
AH$8.21+0.12%vs close
Mkt Cap$3.07B
Float264.25M
O/S374.27M
Vol
$ Vol
RVOL
Inst Own63.6%
SI3.1%
Earnings
Dilution
Bausch Health Companies Inc. logoNYSE:BHC$8.20-7.97%
Phase Distribution
218 lead-sponsored trials·13 active·175 completed
Phase 139
Phase 244
Phase 2/32
Phase 385
Phase 425
Not applicable23
(74 more as collaborator)
Status Overview
Not yet recruiting2
Recruiting6
Active, not recruiting7
Completed175
Stopped23
Expanded access1
Unknown4

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 4
    Completed

    Canadian Aesthetic Experience With Sculptra Therapy

    Poly-L-Lactic Acid

    Skin Aging

    Enrollment
    76
    Start
    Jan 2007
    Primary Completion
    Apr 2008
    Completion
    Apr 2008
    NCT00447551
  • Phase 4
    Completed

    Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness

    Methylnaltrexone bromide

    Opioid-Induced Constipation

    Enrollment
    156
    Start
    Jul 2008
    Primary Completion
    Jan 2013
    Completion
    May 2013
    NCT00672139
  • Phase 4
    Completed

    Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness

    Methylnaltrexone, Placebo

    Opioid-Induced Constipation

    Enrollment
    237
    Start
    Jun 2008
    Primary Completion
    Feb 2013
    Completion
    Feb 2013
    NCT00672477
  • Phase 4
    Completed

    Evaluation of Irritation That Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face.

    Adapalene Gel, Tretinoin Gel

    Acne Vulgaris

    Enrollment
    25
    Start
    Jan 2008
    Primary Completion
    Feb 2008
    Completion
    Feb 2008
    NCT00714714
  • Phase 4
    Withdrawn

    Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer Subjects

    methylnaltrexone, placebo

    Opioid-Induced Constipation

    Enrollment
    0
    Start
    Mar 2009
    Primary Completion
    Aug 2009
    Completion
    Aug 2009
    NCT00858754
  • Phase 4
    Completed

    A Study of Different Use Regimens Using Two Acne Treatments

    benzoyl peroxide wash, Tretinoin gel

    Acne Vulgaris

    Enrollment
    247
    Start
    Feb 2009
    Primary Completion
    Sep 2009
    Completion
    Sep 2009
    NCT00907257
  • Phase 4
    Completed

    Evaluation of Irritation by Two Facial Gels Applied to Opposite Sides of the Face

    Tretinoin gel, Adapalene and Benzoyl peroxide

    Acne Vulgaris

    Enrollment
    26
    Start
    Apr 2009
    Primary Completion
    May 2009
    Completion
    May 2009
    NCT00919191
  • Phase 4
    Completed

    Evaluation of Irritation That Potentially Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face

    Tretinoin Facial Gel, Adapalene/Benzoyl Peroxide Facial Gel

    Acne Vulgaris

    Enrollment
    162
    Start
    Jul 2009
    Primary Completion
    Oct 2009
    Completion
    Oct 2009
    NCT00952523
  • Phase 4
    Completed

    Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL)

    Bexarotene

    Refractory Cutaneous T-cell Lymphoma

    Enrollment
    59
    Start
    Jan 2010
    Primary Completion
    Feb 2014
    Completion
    Feb 2014
    NCT01007448
  • Phase 4
    Completed

    A Study That Evaluates the Decrease in Irritation When Using Additional Acne Treatment Products

    Dapsone plus Tretinoin Gel, Tretinoin Gel

    Acne Vulgaris

    Enrollment
    26
    Start
    Dec 2010
    Primary Completion
    Dec 2010
    Completion
    Jan 2011
    NCT01313728
  • Phase 4
    Completed

    Safety and Efficacy of OsmoPrep® Tablets Versus HalfLytely® and Bisacodyl Tablet Bowel Prep Kit for Colon Cleansing

    Polyethylene glycol, Oral sodium phosphate solution

    Colon Cleansing

    Enrollment
    2,154
    Start
    Sep 2011
    Primary Completion
    Mar 2014
    Completion
    Dec 2014
    NCT01427296
  • Phase 4
    Completed

    The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy

    Rifaximin, Lactulose

    Hepatic Encephalopathy, Cirrhosis

    Enrollment
    222
    Start
    Jan 2013
    Primary Completion
    Dec 2014
    Completion
    Dec 2014
    NCT01842581
  • Phase 4
    Terminated

    Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy

    Placebo, Rifaximin

    Hepatic Encephalopathy

    Enrollment
    6
    Start
    Apr 2013
    Primary Completion
    Feb 2016
    Completion
    Feb 2016
    NCT01846663
  • Phase 4
    Not yet recruiting

    Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder

    bupropion hydrobromide, Placebo

    Major Depressive Disorder

    Enrollment
    246
    Start
    Jul 2027est.
    Primary Completion
    Jul 2030est.
    Completion
    Dec 2030est.
    NCT02129751
  • Phase 4
    Completed

    Maximal Use of Luliconazole Cream 1% in Pediatric Participants With Moderate to Severe Tinea Pedis or Tinea Cruris

    Luliconazole Cream 1%

    Tinea Pedis, Tinea Cruris

    Enrollment
    30
    Start
    Dec 2015
    Primary Completion
    Apr 2016
    Completion
    Apr 2016
    NCT02767271
  • Phase 4
    Completed

    Safety and Efficacy of Product 33525 (Luliconazole Cream 1%) in Pediatric Participants With Tinea Corporis

    Luliconazole Cream 1%, Vehicle Cream

    Tinea Corporis

    Enrollment
    75
    Start
    Feb 2016
    Primary Completion
    Jun 2016
    Completion
    Sep 2016
    NCT02767947
  • Phase 4
    Completed

    Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With Mild to Severe Onychomycosis

    Efinaconazole

    Onychomycosis

    Enrollment
    62
    Start
    Aug 2016
    Primary Completion
    Jan 2019
    Completion
    Jan 2019
    NCT02812771
  • Phase 4
    Active, not recruiting

    An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects

    Brodalumab, Brodalumab

    Psoriasis

    Enrollment
    2
    Start
    Jan 2020
    Primary Completion
    Dec 2028est.
    Completion
    Jun 2029est.
    NCT03240809
  • Phase 4
    Terminated

    Steady-State Pharmacokinetics of Rifaximin 550 mg Tablets in Healthy and Hepatically Impaired Subjects

    Rifaximin

    Severe Hepatic Impairment

    Enrollment
    5
    Start
    Jan 2019
    Primary Completion
    Feb 2020
    Completion
    Feb 2020
    NCT03818672
  • Phase 4
    Active, not recruiting

    A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis

    IDP-122 Lotion

    Psoriasis

    Enrollment
    45
    Start
    Oct 2019
    Primary Completion
    Nov 2026est.
    Completion
    Apr 2027est.
    NCT03987763
  • Phase 4
    Completed

    A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis

    IDP-118 Lotion

    Psoriasis

    Enrollment
    16
    Start
    Mar 2021
    Primary Completion
    Feb 2026
    Completion
    Feb 2026
    NCT03988439
  • Phase 4
    Recruiting

    Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis

    Low Dose Budesonide, High Dose Budesonide

    Ulcerative Colitis

    Enrollment
    70
    Start
    Sep 2023
    Primary Completion
    Dec 2026est.
    Completion
    Jun 2027est.
    NCT04314375
  • Phase 4
    Not yet recruiting

    Dose Ranging Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Rectal Foam in Pediatric Patients Aged 5 to 17 Years With Active, Mild to Moderate Distal Ulcerative Colitis

    High dose budesonide rectal foam, Low dose budesonide rectal foam

    Ulcerative Colitis

    Enrollment
    100
    Start
    Jun 2029est.
    Primary Completion
    Jun 2030est.
    Completion
    Jan 2031est.
    NCT05976802
  • Phase 4
    Recruiting

    Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea

    Rifaximin 200 mg Tablet

    Diarrhea, Gastroenteritis +2

    Enrollment
    54
    Start
    Feb 2026
    Primary Completion
    Apr 2027est.
    Completion
    Jul 2027est.
    NCT07285785
  • Phase 4
    Recruiting

    Study to Assess Safety, Pharmacokinetics, and Treatment Effect of Cabtreo

    CABTREO is a fixed-combination product of clindamycin phosphate 1.2%/BPO 3.1%/adapalene 0.15%.

    Acne Vulgaris

    Enrollment
    100
    Start
    Apr 2026
    Primary Completion
    Dec 2027est.
    Completion
    Dec 2027est.
    NCT07524946

1-25 of 218

…
Search ClinicalTrials.gov for “Bausch Health Companies”